Polymeric penetration enhancers promote humoral immune responses to mucosal vaccines

Journal of Controlled Release

Volumn 183, Issue 1, 2014, Pages 43-50

  Klein, Katja ^a   Mann, Jamie F S ^a   Rogers, Paul ^a   Shattock, Robin J ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Delivery; Immunity; Insulin; Mucosal; Penetration; Vaccination

Indexed keywords

ANTIBODIES; ANTIGENS; BIOCHEMISTRY; BODY FLUIDS; CHITOSAN; INSULIN; PHYSIOLOGY; POLYMERS; VACCINES;

DELIVERY; IMMUNITY; MUCOSAL; PENETRATION; VACCINATION;

IMMUNE SYSTEM;

2,6 O DIMETHYL BETA CYCLODEXTRIN; CHITOSAN; EXCIPIENT; GLUCOSE; GLYCOPROTEIN GP 140; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; PENETRATION ENHANCING AGENT; PHARMACOLOGICAL BIOMARKER; POLYETHYLENEIMINE; POLYMER; RECOMBINANT HUMAN INSULIN; RECOMBINANT VACCINE; TETANUS TOXOID; BETA CYCLODEXTRIN DERIVATIVE; DRUG CARRIER; GP140 ENVELOPE PROTEIN, HUMAN IMMUNODEFICIENCY VIRUS 1; HEPTAKIS(2,6-O-DIMETHYL)BETA-CYCLODEXTRIN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; VIRUS ENVELOPE PROTEIN;

ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CELL MEMBRANE PERMEABILITY; CYTOTOXICITY; DRUG BIOAVAILABILITY; DRUG PENETRATION; EPITHELIUM CELL; FEMALE; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMORAL IMMUNITY; INTERFEROMETRY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SERUM; TIGHT JUNCTION; VACCINATION; VAGINAL SECRETION; ANIMAL; BAGG ALBINO MOUSE; BLOOD; CHEMISTRY; IMMUNOLOGY; MUCOSAL ADMINISTRATION; MUCOSAL IMMUNITY;

ADMINISTRATION, MUCOSAL; AIDS VACCINES; ANIMALS; BETA-CYCLODEXTRINS; CHITOSAN; DRUG CARRIERS; ENV GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; FEMALE; IMMUNITY, HUMORAL; IMMUNITY, MUCOSAL; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; MICE, INBRED BALB C; POLYETHYLENEIMINE; POLYMERS; TETANUS TOXOID; VACCINES, SYNTHETIC;

EID: 84898040085     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2014.03.018     Document Type: Article

References (51)

1. M.R. Prausnitz, and R. Langer Transdermal drug delivery Nat. Biotechnol. 26 11 2008 1261 1268
2. M.R. Neutra, and P.A. Kozlowski Mucosal vaccines: the promise and the challenge Nat. Rev. Immunol. 6 2 2006 148 158 (Pubitemid 43361590)
3. N. Lycke Recent progress in mucosal vaccine development: potential and limitations Nat. Rev. Immunol. 12 8 2012 592 605
4. T. Mosmann Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays J. Immunol. Methods 65 1-2 1983 55 63 (Pubitemid 14203433)
5. P.J. Carney, A.S. Lipatov, A.S. Monto, R.O. Donis, and J. Stevens Flexible label-free quantitative assay for antibodies to influenza virus hemagglutinins Clin. Vaccine Immunol. 17 9 2010 1407 1416
6. I.M. Helander, H.L. Alakomi, K. Latva-Kala, and P. Koski Polyethyleneimine is an effective permeabilizer of gram-negative bacteria Microbiology 143 Pt 10 1997 3193 3199 (Pubitemid 27470167)
7. I.M. Helander, K. Latva-Kala, and K. Lounatmaa Permeabilizing action of polyethyleneimine on Salmonella typhimurium involves disruption of the outer membrane and interactions with lipopolysaccharide Microbiology 144 Pt 2 1998 385 390 (Pubitemid 28067743)
8. E. Marttin, J.C. Verhoef, and F.W. Merkus Efficacy, safety and mechanism of cyclodextrins as absorption enhancers in nasal delivery of peptide and protein drugs J. Drug Target. 6 1 1998 17 36 (Pubitemid 28499586)
9. I. Jabbal-Gill, A.N. Fisher, R. Rappuoli, S.S. Davis, and L. Illum Stimulation of mucosal and systemic antibody responses against Bordetella pertussis filamentous haemagglutinin and recombinant pertussis toxin after nasal administration with chitosan in mice Vaccine 16 20 1998 2039 2046 (Pubitemid 28473954)
10. E.A. McNeela, D. O'Connor, I. Jabbal-Gill, L. Illum, S.S. Davis, M. Pizza, S. Peppoloni, R. Rappuoli, and K.H. Mills A mucosal vaccine against diphtheria: formulation of cross reacting material (CRM(197)) of diphtheria toxin with chitosan enhances local and systemic antibody and Th2 responses following nasal delivery Vaccine 19 9-10 2000 1188 1198 (Pubitemid 32008285)
11. R.C. Read, S.C. Naylor, C.W. Potter, J. Bond, I. Jabbal-Gill, A. Fisher, L. Illum, and R. Jennings Effective nasal influenza vaccine delivery using chitosan Vaccine 23 35 2005 4367 4374 (Pubitemid 40991223)
12. M. Shan, P.J. Klasse, K. Banerjee, A.K. Dey, S.P. Iyer, R. Dionisio, D. Charles, L. Campbell-Gardener, W.C. Olson, R.W. Sanders, and J.P. Moore HIV-1 gp120 mannoses induce immunosuppressive responses from dendritic cells PLoS Pathog. 3 11 2007 e169
13. S. Hong, P.R. Leroueil, E.K. Janus, J.L. Peters, M.M. Kober, M.T. Islam, B.G. Orr, J.R. Baker Jr., and M.M. Banaszak Holl Interaction of polycationic polymers with supported lipid bilayers and cells: nanoscale hole formation and enhanced membrane permeability Bioconjug. Chem. 17 3 2006 728 734 (Pubitemid 43794383)
14. L. Hovgaard, and H. Brondsted Drug delivery studies in Caco-2 monolayers. IV. Absorption enhancer effects of cyclodextrins Pharm. Res. 12 9 1995 1328 1332
15. L. Illum, N.F. Farraj, and S.S. Davis Chitosan as a novel nasal delivery system for peptide drugs Pharm. Res. 11 8 1994 1186 1189 (Pubitemid 24259861)
16. S.L. Hillier, T. Moench, R. Shattock, R. Black, P. Reichelderfer, and F. Veronese In vitro and in vivo: the story of nonoxynol 9 J. Acquir. Immune Defic. Syndr. 39 1 2005 1 8 (Pubitemid 40617012)
17. D.L. Patton, Y.T. Cosgrove Sweeney, L.K. Rabe, and S.L. Hillier Rectal applications of nonoxynol-9 cause tissue disruption in a monkey model Sex. Transm. Dis. 29 10 2002 581 587
18. D.L. Patton, G.G. Kidder, Y.C. Sweeney, L.K. Rabe, and S.L. Hillier Effects of multiple applications of benzalkonium chloride and nonoxynol 9 on the vaginal epithelium in the pigtailed macaque (Macaca nemestrina) Am. J. Obstet. Gynecol. 180 5 1999 1080 1087 (Pubitemid 29258998)
19. A.C. Hunter Molecular hurdles in polyfectin design and mechanistic background to polycation induced cytotoxicity Adv. Drug Deliv. Rev. 58 14 2006 1523 1531 (Pubitemid 44820504)
20. K. Regnstrom, E.G. Ragnarsson, M. Koping-Hoggard, E. Torstensson, H. Nyblom, and P. Artursson PEI - a potent, but not harmless, mucosal immuno-stimulator of mixed T-helper cell response and FasL-mediated cell death in mice Gene Ther. 10 18 2003 1575 1583 (Pubitemid 37063263)
21. F. Wegmann, K.H. Gartlan, A.M. Harandi, S.A. Brinckmann, M. Coccia, W.R. Hillson, W.L. Kok, S. Cole, L.P. Ho, T. Lambe, M. Puthia, C. Svanborg, E.M. Scherer, G. Krashias, A. Williams, J.N. Blattman, P.D. Greenberg, R.A. Flavell, A.E. Moghaddam, N.C. Sheppard, and Q.J. Sattentau Polyethyleneimine is a potent mucosal adjuvant for viral glycoprotein antigens Nat. Biotechnol. 30 9 2012 883 888
22. C.Y. Cui, W.L. Lu, L. Xiao, S.Q. Zhang, Y.B. Huang, S.L. Li, R.J. Zhang, G.L. Wang, X. Zhang, and Q. Zhang Sublingual delivery of insulin: effects of enhancers on the mucosal lipid fluidity and protein conformation, transport, and in vivo hypoglycemic activity Biol. Pharm. Bull. 28 12 2005 2279 2288 (Pubitemid 41757421)
23. Z. Degim, T. Degim, F. Acarturk, D. Erdogan, C. Ozogul, and M. Koksal Rectal and vaginal administration of insulin-chitosan formulations: an experimental study in rabbits J. Drug Target. 13 10 2005 563 572 (Pubitemid 43101955)
24. F.W. Merkus, J.C. Verhoef, S.G. Romeijn, and N.G. Schipper Absorption enhancing effect of cyclodextrins on intranasally administered insulin in rats Pharm. Res. 8 5 1991 588 592
25. A.M. Dyer, M. Hinchcliffe, P. Watts, J. Castile, I. Jabbal-Gill, R. Nankervis, A. Smith, and L. Illum Nasal delivery of insulin using novel chitosan based formulations: a comparative study in two animal models between simple chitosan formulations and chitosan nanoparticles Pharm. Res. 19 7 2002 998 1008 (Pubitemid 34804242)
26. D.I. Albu, A. Jones-Trower, A.M. Woron, K. Stellrecht, C.C. Broder, and D.W. Metzger Intranasal vaccination using interleukin-12 and cholera toxin subunit B as adjuvants to enhance mucosal and systemic immunity to human immunodeficiency virus type 1 glycoproteins J. Virol. 77 10 2003 5589 5597 (Pubitemid 36538951)
27. G.A. Van Roey, M.A. Arias, J.S. Tregoning, G. Rowe, and R.J. Shattock Thymic stromal lymphopoietin (TSLP) acts as a potent mucosal adjuvant for HIV-1 gp140 vaccination in mice Eur. J. Immunol. 42 2 2012 353 363
28. J.F. Mann, P.F. McKay, S. Arokiasamy, R.K. Patel, J.S. Tregoning, and R.J. Shattock Mucosal application of gp140 encoding DNA polyplexes to different tissues results in altered immunological outcomes in mice PLoS One 8 6 2013 e67412
29. C. Hervouet, C. Luci, N. Cuburu, M. Cremel, S. Bekri, L. Vimeux, C. Maranon, C. Czerkinsky, A. Hosmalin, and F. Anjuere Sublingual immunization with an HIV subunit vaccine induces antibodies and cytotoxic T cells in the mouse female genital tract Vaccine 28 34 2010 5582 5590
30. V. Buffa, K. Klein, L. Fischetti, and R.J. Shattock Evaluation of TLR agonists as potential mucosal adjuvants for HIV gp140 and tetanus toxoid in mice PLoS One 7 12 2012 e50529
31. D.J. Lewis, C.A. Fraser, A.N. Mahmoud, R.C. Wiggins, M. Woodrow, A. Cope, C. Cai, R. Giemza, S.A. Jeffs, M. Manoussaka, T. Cole, M.P. Cranage, R.J. Shattock, and C.J. Lacey Phase I randomised clinical trial of an HIV-1(CN54), Clade C, trimeric envelope vaccine candidate delivered vaginally PLoS One 6 9 2011 e25165
32. M.P. Cranage, C.A. Fraser, Z. Stevens, J. Huting, M. Chang, S.A. Jeffs, M.S. Seaman, A. Cope, T. Cole, and R.J. Shattock Repeated vaginal administration of trimeric HIV-1 clade C gp140 induces serum and mucosal antibody responses Mucosal Immunol 3 1 2010 57 68
33. F. Wegmann, G. Krashias, K. Luhn, K. Laamanen, S. Vieira, S.A. Jeffs, R.J. Shattock, and Q.J. Sattentau A novel strategy for inducing enhanced mucosal HIV-1 antibody responses in an anti-inflammatory environment PLoS One 6 1 2011 e15861
34. M.W. Russell Immunization for protection of the reproductive tract: a review Am. J. Reprod. Immunol. 47 5 2002 265 268 (Pubitemid 34464186)
35. C.A. Black, L.C. Rohan, M. Cost, S.C. Watkins, R. Draviam, S. Alber, and R.P. Edwards Vaginal mucosa serves as an inductive site for tolerance J. Immunol. 165 9 2000 5077 5083
36. K.J. Doores, C. Bonomelli, D.J. Harvey, S. Vasiljevic, R.A. Dwek, D.R. Burton, M. Crispin, and C.N. Scanlan Envelope glycans of immunodeficiency virions are almost entirely oligomannose antigens Proc. Natl. Acad. Sci. U. S. A. 107 31 2010 13800 13805
37. L. de Witte, A. Nabatov, M. Pion, D. Fluitsma, M.A. de Jong, T. de Gruijl, V. Piguet, Y. van Kooyk, and T.B. Geijtenbeek Langerin is a natural barrier to HIV-1 transmission by Langerhans cells Nat. Med. 13 3 2007 367 371 (Pubitemid 46376681)
38. K. Banerjee, S. Andjelic, P.J. Klasse, Y. Kang, R.W. Sanders, E. Michael, R.J. Durso, T.J. Ketas, W.C. Olson, and J.P. Moore Enzymatic removal of mannose moieties can increase the immune response to HIV-1 gp120 in vivo Virology 389 1-2 2009 108 121
39. M. Koch, M. Pancera, P.D. Kwong, P. Kolchinsky, C. Grundner, L. Wang, W.A. Hendrickson, J. Sodroski, and R. Wyatt Structure-based, targeted deglycosylation of HIV-1 gp120 and effects on neutralization sensitivity and antibody recognition Virology 313 2 2003 387 400 (Pubitemid 37045357)
40. Y. Li, B. Cleveland, I. Klots, B. Travis, B.A. Richardson, D. Anderson, D. Montefiori, P. Polacino, and S.L. Hu Removal of a single N-linked glycan in human immunodeficiency virus type 1 gp120 results in an enhanced ability to induce neutralizing antibody responses J. Virol. 82 2 2008 638 651
41. Y. Wan, L. Liu, L. Wu, X. Huang, L. Ma, and J. Xu Deglycosylation or partial removal of HIV-1 CN54 gp140 V1/V2 domain enhances env-specific T cells AIDS Res Hum Retroviruses 25 6 2009 607 617
42. M.E. Davis, and M.E. Brewster Cyclodextrin-based pharmaceutics: past, present and future Nat. Rev. Drug Discov. 3 12 2004 1023 1035 (Pubitemid 39642365)
43. K. Uekama Design and evaluation of cyclodextrin-based drug formulation Chem Pharm Bull (Tokyo) 52 8 2004 900 915 (Pubitemid 41701863)
44. R. Scherliess, S. Buske, K. Young, B. Weber, T. Rades, and S. Hook In vivo evaluation of chitosan as an adjuvant in subcutaneous vaccine formulations Vaccine 31 42 2013 4812 4819
45. J. Holmgren, and C. Czerkinsky Mucosal immunity and vaccines Nat. Med. 11 Suppl. 4 2005 S45 S53
46. A. Kantele, M. Hakkinen, Z. Moldoveanu, A. Lu, E. Savilahti, R.D. Alvarez, S. Michalek, and J. Mestecky Differences in immune responses induced by oral and rectal immunizations with Salmonella typhi Ty21a: evidence for compartmentalization within the common mucosal immune system in humans Infect. Immun. 66 12 1998 5630 5635 (Pubitemid 28531815)
47. C. Balmelli, R. Roden, A. Potts, J. Schiller, P. De Grandi, and D. Nardelli-Haefliger Nasal immunization of mice with human papillomavirus type 16 virus-like particles elicits neutralizing antibodies in mucosal secretions J. Virol. 72 10 1998 8220 8229 (Pubitemid 28421819)
48. E.L. Johansson, L. Wassen, J. Holmgren, M. Jertborn, and A. Rudin Nasal and vaginal vaccinations have differential effects on antibody responses in vaginal and cervical secretions in humans Infect. Immun. 69 12 2001 7481 7486 (Pubitemid 33086573)
49. C. Dupuy, D. Buzoni-Gatel, A. Touze, D. Bout, and P. Coursaget Nasal immunization of mice with human papillomavirus type 16 (HPV-16) virus-like particles or with the HPV-16 L1 gene elicits specific cytotoxic T lymphocytes in vaginal draining lymph nodes J. Virol. 73 11 1999 9063 9071 (Pubitemid 29487059)
50. W.S. Gallichan, and K.L. Rosenthal Specific secretory immune responses in the female genital tract following intranasal immunization with a recombinant adenovirus expressing glycoprotein B of herpes simplex virus Vaccine 13 16 1995 1589 1595
51. K. Imaoka, C.J. Miller, M. Kubota, M.B. McChesney, B. Lohman, M. Yamamoto, K. Fujihashi, K. Someya, M. Honda, J.R. McGhee, and H. Kiyono Nasal immunization of nonhuman primates with simian immunodeficiency virus p55gag and cholera toxin adjuvant induces Th1/Th2 help for virus-specific immune responses in reproductive tissues J. Immunol. 161 11 1998 5952 5958 (Pubitemid 28535963)